Alteplase vs. urokinase treatment after minimally invasive surgery for spontaneous intracerebral hemorrhage: a single-center experience

连立飞,梁奇明,许峰,潘超,朱遂强,王芙蓉
DOI: https://doi.org/10.11817/j.issn.1673-9248.2021.06.008
2021-01-01
Abstract:Objective:To investigate the efficacy and safety of recombinant tissue-type plasminogen activator (rt-PA, Alteplase) and urokinase after minimally invasive surgery (MIS) for spontaneous supratentorial intracerebral hemorrhage (ICH).Methods:Patients with spontaneous supratentorial ICH ≥20 ml, who were treated with MIS plus rt-PA (rt-PA group) or urokinase (urokinase group) in Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, were retrospectively included from our prospective database between October 2011 and November 2013. The clinical features, imaging data, as well as adverse events and functional outcome at 3 months were analyzed. The residual hematoma volume, mass effect and clot removal rate at the end of treatment in the two groups were analyzed by Student's t test. The outcome at 3 months, complications and mortality during hospitalization were assessed by the χ2 test.Results:A total of 136 patients were included, that was 80 in rt-PA group and 56 in urokinase group. The baseline characteristics between the two groups were similar. Compared with the urokinase group, patients in the rt-PA group had a higher hematoma clearance rate (83.7%±20.0% vs 69.5%±26.0%, t=3.597, P=0.001), smaller residual hematoma volume [(9.2±7.4) ml vs (13.8±8.3) ml, t=3.393, P=0.001], and more reduced mass at the end of MIS treatment [(5.3±3.6) mm vs (3.2±3.1) mm, t=3.541, P=0.001]. The mortality at 3 months in the rt-PA group was significantly lower than that in urokinase group (2.5% vs 12.5%, χ2=5.291, P=0.032), and there was a tendency of the improvement of 3-month functional outcome (32.5% vs 21.4%, χ2=2.001, P=0.157). There was no difference between the two groups in infectious complications and adverse events. The recurrence of bleeding after MIS was 6.6% (9/136).Conclusion:MIS combined with rt-PA or urokinase can safely remove the hematoma in patients with supratentorial ICH. Intra-clot rt-PA treatment after MIS has a likely slight superiority over urokinase for hematoma removal, which may further help to reduce the mortality.
What problem does this paper attempt to address?